Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | MPC2 | O95563 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14213721 | 0.88 | PPARG (0.50) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL8282079 | 0.87 | PPARG (0.53) | PPARGMPC2CYP2C8CYP2C9NR4A2 | |
| SCHEMBL8282078 | 0.85 | PPARG (0.53) | PPARGMPC2CYP2C8CYP2C9NR4A2 | |
| SCHEMBL8282081 | 0.85 | PPARG (0.70) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL8282085 | 0.84 | PPARG (0.66) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL6930536 | 0.83 | PPARG (0.73) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL14213724 | 0.82 | PPARG (0.53) | PPARGMPC2CYP2C8CYP2C9VNN1 | |
| SCHEMBL8282082 | 0.80 | LMNA (0.53) | PPARGMPC2CYP2C8CYP2C9NR4A2 | |
| SCHEMBL14213592 | 0.80 | PPARG (0.51) | PPARGFFAR1CFTRFFAR4 | |
| SCHEMBL14213585 | 0.80 | PPARG (0.51) | PPARGFFAR1CFTRFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| US-9126959-B2 | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150051406-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8912335-B2 | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130053350-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120322728-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120316138-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120309975-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053350-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PPARD, PPARG, PPARA | PPARG 2/4885MPC2 115/4885CYP2C8 2493/4885 |
| US-20120309975-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | PPARD, PPARG, PPARA | PPARG 2/4885MPC2 131/4885CYP2C8 1883/4885 |
| US-20150051406-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | PPARD, PPARG, PPARA | PPARG 2/4885MPC2 131/4885CYP2C8 1883/4885 |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | PPARD, PPARG, PPARA | PPARG 2/4885MPC2 85/4885CYP2C8 997/4885 |
| US-20120316138-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | PPARD, PPARA, PPARG | PPARG 3/4885MPC2 112/4885CYP2C8 385/4885 |
| US-20120322728-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | GLP1R, PPARD, PPARA | PPARG 4/4885MPC2 216/4885CYP2C8 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.